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ated ischemic steal.
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Surg 2008;48:1559-65.Submitted Feb 26, 2013; accepted Apr 23, 2013.DISCUSSIONDr Linda Harris (Buffalo, NY). Have you incorporated into
your modeling the vasoreactivity changes? One of the problems we
have is that arteries aren’t always nice soft vessels. Do your models,
either the plastic model or the computerized model, take into
account calciﬁcation and loss of vasoreactivity?
Dr Ankur Chandra. Actually, what we’re working on now
is currently a method of being able to use angiographic method
to determine downstream vascular resistance and then incorpo-
rating that vascular resistance, such as calciﬁcations, into the
program, which will allow a modiﬁcation of that patient-speciﬁc
diagram.
Dr April Boyd (Winnipeg, Manitoba, Canada). Have you
done any particle velocimetry to look at the actual ﬂow dynamics
in the model to see how closely you’re predicting ﬂow?
Dr Chandra. That’s a terriﬁc idea. And in fact, that’s one of
our next set of experiments is both validating the computationalﬂuid dynamic model with the in vitro model. And the beneﬁt of
the in vitro modeling is that we could very easily input particles
or dye or other characteristics, image them, and do exactly that.
So that’s what we do plan to do in the future.
Dr Peter Lawrence (Los Angeles, Calif). Please comment
about the role of imaging, and particularly MRA, in your model.
A lot of what you showed us could be imaged with MRA,
including not only larger vessel diameter and anatomy, but also
ﬂow, not only through the vessels but also the tissues.
Dr Chandra. I think that’s actually exactly right. In fact, the
next stage that we’re going to expand into is obviously gathering
clinical data from clinical imaging, so either angiographic imaging
at the time of a ﬁstulogram or MRI imaging. Because obviously we
have already correlated this with preliminary clinical data, but
correlating it over a larger scale will require both either MRI
and/or angiographies.
